申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1035115A1
公开(公告)日:2000-09-13
The present invention relates to compounds of the general formula
wherein
Ris hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;
R1is hydrogen or halogen; or
R and R1may be together -CH=CH-CH=CH-;
R2 and R2'are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or
R2 and R2'may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy;
R3is hydrogen, lower alkyl or form a cycloalkyl group;
R4is hydrogen, -N(R5)2, -N(R5)(CH2)nOH, -N(R5)S(O)2-lower alkyl, -N(R5)S(O)2-phenyl, -N=CH-N(R5)2, -N(R5)C(O)R5 or a cyclic tertiary amine of the group
R5is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl;
R6is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group,
Xis -C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5)C(O)-, or -N(R5)(CH2)m-;
nis 0-4; and
mis 1 or 2;
and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK- 1 receptor. They may be used for the treatment of diseases, which relate to NK- 1 receptor antagonists.
本发明涉及通式如下的化合物
式中
Ris氢、低级烷基、低级烷氧基、卤素或三氟甲基;
R1 是氢或卤素;或
R和R1可以是-CH=CH-CH=CH-;
R2 和 R2'彼此独立地为氢、卤素、三氟甲基、低级烷氧基或氰基;或
R2 和 R2'可以同时为-CH=CH-CH=CH-,任选被一个或两个选自低级烷基或低级烷氧基的取代基取代;
R3 是氢、低级烷基或形成环烷基;
R4 是氢、-N(R5)2、-N(R5)(CH2)nOH、-N(R5)S(O)2-低级烷基、-N(R5)S(O)2-苯基、-N=CH-N(R5)2、-N(R5)C(O)R5 或以下基团的环状叔胺
R5 相互独立地为氢、C3-6-环烷基、苄基或低级烷基;
R6 是氢、羟基、低级烷基、-(CH2)nCOO-低级烷基、-N(R5)CO-低级烷基、羟基-低级烷基、氰基、-(CH2)nO(CH2)nOH、-CHO 或可选择通过亚烷基键合的 5 或 6 位杂环基团、
X是-C(O)N(R5)-、-(CH2)mO-、-(CH2)mN(R5)-、-N(R5)C(O)-或-N(R5)(CH2)m-;
n 为 0-4;以及
误差为 1 或 2;
及其药学上可接受的酸加成盐。式 I 的化合物对 NK- 1 受体具有很高的亲和力。它们可用于治疗与 NK- 1 受体拮抗剂有关的疾病。